Skip to content

10770 Wateridge Circle, Suite 210, San Diego, CA 92121

(858) 362-6295

info@anaptysbio.com

AnaptysBio logo
AnaptysBio logo
  • Home
  • About Us
  • Financial Collaborations
    • Our Partnerships
    • Key Catalysts
    • Financials
  • Investors
    • Overview
    • News
    • Presentations & Events
    • Governance
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Investor FAQs
    • Contact

Why amet lorem dolor glavrida agestas

Industry news, Useful articlesBy Justin BeachMay 8, 2025

Ipsum nulla – lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

AnaptysBio logo

Call us

(858) 732-0299

Email

info@anaptysbio.com

Quick links

  • About Us
  • Financial Collaborations
  • Investors

© 2026 AnaptysBio, Inc. All rights reserved.

Privacy policy
Terms of use
powered by
Go to Top

Menu

  • Home
  • About Us
  • Financial Collaborations
    • Our Partnerships
    • Key Catalysts
    • Financials
  • Investors
    • Overview
    • News
    • Presentations & Events
    • Governance
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Investor FAQs
    • Contact
AnaptysBio logo
AnaptysBio now exclusively manages the financial collaborations relating to Jemperli with GSK and imsidolimab with Vanda

Effective April 20, 2026, Anaptys has spun off its biopharma business, including its therapies, into a new company, First Tracks Biotherapeutics

Stay on AnaptysBio.com
Continue to FirstTracksBio.com

Why amet lorem dolor glavrida agestas

Add Your Heading Text Here